Eli Lilly and Company

Zeneca Limited

Daniel Ray Mayhugh

Nathan Bryan Mantlo

Xiaodong Wang

Guoxin Zhu

Scott Eugene Conner

Jeffrey Michael Schkeryantz

Stephen A Hitchcock

Timothy Alan Shepherd

Louis Nickolaus Jungheim

Yanping Xu

Keith Russell

William Wilson Turner, Jr

Peter S Borromeo

Jeffrey Daniel Cohen

Ana Maria Escribano

James Roy Empfield

Albert Khilevich

Douglas Linn Gernert

Maria Carmen Fernandez

Ana Isabel Mateo Herranz

Eva Maria Martin De La Nava

George Stuart Gregory

Stacy Kay Henle

Guoqing Cao

Paul Leslie Ornstein

Alan M Warshawsky

Donald Paul Matthews

Jon Kevin Reel

Leonard Larry Winneroski, Jr

Warren Jaye Porter

Christopher Cioffi

Richard Craig Thompson

Michael Gregory Bell

Samuel James Dominianni

Robert Jason Herr

Winton Dennis Jones, Jr

Patrick Gianpietro Spinazze

Lynn Stacy Gossett

Daryl Lynn Smith

Richard Duane Johnston

Sean Patrick Hollinshead

Freddie Craig Stevens

Kevin Matthew Gardinier

Deyi Zhang

Patric James Hahn

Peter Ambrose Lander

Jonathan Edward Green

James Allen Knobelsdorf

Bin Liu

Christopher Randall Schmid

Ashraf Saeed

Todd Fields

Jennifer Ann Vance

Garret Jay Etgen

Jeffrey Michael Witkin

A TARP &#x3b3;8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N;A is andRis as defined herein;its pharmaceutically acceptable salts, uses, and methods for its preparation are described.

[object Object]

The present invention provides certain imidazole carboxamide derivatives, pharmaceutical compositions thereof, methods of using the same and processes for preparing the same.

Imidazole carboxamides

Compounds of formula I wherein n, m, p, q, y, RR, R, R, R, and Rare as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.

Compounds and methods for treating dislipidemia

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

The present invention is directed to a method of treatment by modulating a peroxisome proliferator activated receptor by employing a compound of Structural Formula (I). The variables in I are defined herein. Also included are compounds, methods of making compounds, and pharmaceutical compositions. The compounds of the present invention are believed to be effective in treating and preventing Syndrome X, Type H diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis, and other disorders related to Syndrome X and cardiovascular diseases.

Fused heterocyclic derivatives as PPAR modulators

The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R, R, R, R, R, and Rare as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.

Compounds and methods for treating dyslipidemia

The present invention is directed to a compound, {2-Methyl-4-[3-methyl-1-(4-trifluoromethyl-phenyl)-1H-pyrazol-4-ylmethylsulfanyl]-phenoxy}-acetic acid and pharmaceutical uses thereof.

Pyrazole derivative as PPAR modulator

The present invention is directed to compounds represented by the following structural formula, and pharmaceutically acceptable salts, solvates and hydrates thereof, R1 is a substituted or unsubstituted group selected from C-Calkyl, aryl-C-alkyl, heteroaryl-C-alkyl, C-Ccycloalkylaryl-C-alkyl or phenyl. W is O or S. R2 is H or a substituted or unsubstituted group selected from C-Calkyl, C-Ccycloalkyl and heteroaryl. X is a C-Calkylene linker wherein one carbon atom of the linker may be replaced with O, NH or S. Y is C, O, S, NH or a single bond. Furthermore, E is (CH)COOH, wherein n is 0, 1, 2 or 3, or C(R3)(R4)A, wherein A is an acidic functional group such as carboxyl, carboxamide substituted or unsubstituted sulfonamide, or substituted or unsubstituted tetrazole. R3 is H, saturated or unsaturated C-Calkyl, C-Calkoxy. Additionally, R4 is H, halo, a substituted or unsubstituted group selected from C-Calkyl, C-Calkoxy, C-Ccycloalkyl, arylC-Calkyl and phenyl, or R3 and R4 are combined to form a C-Ccycloalkyl.

Peroxisome proliferator activated receptor alpha agonists

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal ornithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Ring modified cyclic peptide analogs

A method for modifying the cyclic peptide ring system of Echinocandin-type compounds to produce new analogs having antifungal activity is provided. The inventive process comprises opening the cyclic peptide ring, cleaving the terminal omithine unit, inserting at least one new amino acid or other synthetic unit and closing the ring to produce a new cyclic peptide ring structure. The process allows one to incorporate features such as water-solubility into the cyclic peptide ring nucleus, sites for further modification, increase or decrease the number of amino acid or peptide units within the ring nucleus, and increase or decrease the total number of members within the ring. The invention further provides novel Echinocandin type compounds and their use as antifungal or anti-parasitic agents.

Compounds of formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and A-B have any of the meanings given in the specification, and their pharmaceutically acceptable salts are useful in the treatment of urinery incontinence. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

Therapeutic heterocyclyl amionosulfonyl phenyl compounds

Aminosulfonylphenyl compounds for treating urinary incontinence

Growing community of inventors

Carmel, IN, United States of America

Daniel Ray Mayhugh